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Abstract
Several variables, including age, are known to influence anxiety. Previous exposure to the elevated-plus maze (EPM) is known to modify
emotional behaviour as retesting in the EPM at a standard age of 3 months increases open-arm avoidance and attenuates the effects of anxiolytic
drugs. This study analysed whether similar results are obtained when older animals are subjected to these experimental paradigms. Overall,
increasing age was associated with more signs of anxiety. Additionally, we observed a paradoxical behaviour pattern in aged-subjects that
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dere re-exposed to the EPM, with mid-aged and old rats failing to display open arm avoidance (OAA) in the second trial; this qualitative shift
n emotional behaviour was not associated with decreased locomotion. An examination of how age influences responsiveness to anxiolytic
rugs, with or without previous maze experience, was also conducted. Midazolam (0.5 and 1 mg/kg) proved anxiolytic in maize-naive young
nimals; in marked contrast, in older animals midazolam at 1 mg/kg resulted in sedation but not anxiolyis. One trial tolerance to midazolam
as evident in animals of both ages that were subjected to a second EPM trial; the latter phenomenon was apparently accentuated in older
nimals as they do not show open arm avoidance upon re-exposure to the EPM. These data suggest that the age-associated ‘resistance’ to
nxiolytic drugs might be related to a qualitative shift in emotional behaviour.
2005 Elsevier B.V. All rights reserved.
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. Introduction
The elevated-plus maze (EPM) is currently the most pop-
lar and reliable animal test to evaluate anxiety behaviour in
odents [21,33]. It relies on the conflict of the natural aver-
ion of rodents to open spaces with the drive to explore a new
nvironment [42] and has been extensively validated [27,32];
n accordance, it has proven to be essential in the screening of
ew anxiolytic drugs [11]. There are several variables known
o influence behaviour in EPM [33]; briefly, they can be di-
ided in those depending on the subject (e.g. specie, strain,
ender and age) and those depending on environment (e.g.
ousing, prior handling or stress, lighting levels). Previous
xposure to the maze is recognized as an important modi-
∗ Corresponding author. Tel.: +351 253 604806; fax: +351 253 604809.
E-mail address: njcsousa@ecsaude.uminho.pt (N. Sousa).
fier of performance; indeed, retest of rodents in the EPM in-
creases open arm avoidance (OAA) [2,12,16,19,23,34–36].
This OAA effect seems to be progressive, starting around the
second minute of trial 1 and may even increase with further
retesting [22,35].
Prior maze experience is also known to reduce or even
abolish the anxiolytic effects of drugs that bind to the
GABA-A receptor complex such as benzodiazepines, ethanol
or phenobarbital [3,15,17,34], as well as drugs that block
NMDA/glycine-B receptor activity such as memantine [4].
This loss of anxiolytic effect of drugs in the trial 2 of the
EPM, designated as “one trial tolerance” (OTT) [14], has also
been observed in other animal models of anxiety [20,24,30].
The phenomenon of OTT, which seems to be independent of
the drug treatment on trial 1 or the material of the maze [14],
occurs with inter-test intervals ranging from 24 h to 2 weeks
[14,34].
166-4328/$ – see front matter © 2005 Elsevier B.V. All rights reserved.
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Different hypotheses have been advanced to explain the
effect of prior maze experience in the increase of OAA and
the phenomenon of OTT such as locomotor habituation [12],
acquisition of a phobic avoidance of open arms [15,34] or a
qualitative shift in the emotional state during trial 2 [22]. Yet,
the ethologic and biologic significance of the behavioural
changes elicited by prior maze experience still remain un-
clear.
Changes in emotional behaviour represent one of the most
important aspects of aging in both humans and rodents.
Taking into account the altering behaviour patterns of rats
with different ages in the EPM [6,25] and the relevance of
prior experiences in the process of avoidance learning we
designed the present study to further characterise the ef-
fect of prior maze exposure on the increase of OAA and
the OTT phenomenon in different stages of the rat adult
lifetime.
2. Materials and methods
2.1. Animals
Male Wistar rats (Charles Rivers Laboratories, Barcelona,
Spain), aged 2, 3, 12 and 18 months were used; the weights of
animals aged between 2 and 3 months ranged between 200 and
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2.4. Evaluation of the open arm avoidance effect
To evaluate the OAA effect, the 48 rats used were divided into
four different age groups (n= 12) of 2, 3, 12 and 18 months respec-
tively. The animals were submitted to two trials in the EPM, with
an intertrial interval of 24 h.
2.5. One trial tolerance to midazolam
Among the 90 rats used to assess the OTT phenomenon to mida-
zolam, 47 were maze-naive while 43 were pre-exposed to the EPM
with an intertrial interval of 24 h without drug treatment (maze-
experienced). Both groups were subdivided in two different age
groups (3 and 12 months). Within each group, animals were ran-
domly allocated to different treatment conditions ((saline, n= 8; 0.5,
n= 7 or 1, n= 7) mg/kg midazolam). The injection-test interval em-
ployed was 15 min. Midazolam (Roche, Switzerland) was dissolved
shortly before use in a 0.9% saline solution (which, alone, served as a
vehicle control). The solutions were administered intraperitoneally
in a volume of 0.15 ml/100 g.
2.6. Behavioural analysis
The standard behavioural parameters analysed for each animal
in the EPM were the amount of time spent in the central area, open
and closed arms, the number of entries in the open and closed arms
and the number of explorations of the open arms. In addition, these
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o50 g while the older animals weighed 500 and 750 g. Animals were
oused in a room adjacent to the laboratory, in groups of four (cage
ize 60 cm× 40 cm× 20 cm), under standard laboratory conditions
ith an artificial light/dark cycle of 12/12 h (lights on at 8 a.m.), tem-
erature of 22 ◦C and free access to food and water. Animals were
aken to the test laboratory at least 1 h prior to testing and all exper-
mental sessions were conducted during the diurnal phase, between
2:00 and 18:00 h. All procedures were carried out in accordance
ith European Union Directive 86/609/EEC and NIH guidelines on
nimal care and experimentation.
.2. Apparatus
The EPM was made of black polypropylene (ENV-
60; MedAssociates, VT, USA), consisted of two oppo-
ite open arms (50.8 cm× 10.2 cm) and two enclosed arms
50.8 cm× 10.2 cm× 40.6 cm) elevated 72.4 cm above the floor.
he junction area between the four arms measured 10 cm× 10 cm.
raised edge (0.5 cm) on the open arms provided additional grip
or the rats.
.3. Procedures
The experimental room was lit by 40 W fluorescent lamps
ounted above the maze so that all arms were equally illumi-
ated (300 lx at the maze floor level). Rats were placed individu-
lly in the centre of the maze facing a closed arm and were allowed
min of free exploration. Behavioural parameters were recorded
ith the use of an infra-red photobeam system connected to a
omputer with specific software (MedPCIV, MedAssociates, VT,
SA). After each trial, the maze was cleaned with a 10% ethanol
olution.ata were used to calculate the number of entries in the closed
rms as a general locomotion activity measure, the percentage of
ime spent in open arms (%OT: open arm time/300× 100), the per-
entage of open arm entries [%OE: open entries/(open + closed en-
ries)× 100] and the risk assessment (RA) behaviour defined as fol-
ows: RA = [number of explorations/(300− open arm time)]× 60.
he RA measure allows estimating the frequency of explorations
rom protected areas of the maze per minute and has proven to be
ery sensitive to changes in anxiety behaviour [10,18]. Measures of
ariation between trial 1 and 2 were calculated for the percentages
f open arm time and open arm entries.
.7. Statistics
In the evaluation of the open arm avoidance effect, data from
oth trials was analysed by two-factor (age group× trial) repeated
easures analysis of variance (ANOVA). The one trial tolerance
o midazolam was analysed by three-factor (age group×maze ex-
erience× drug) analysis of variance (ANOVA). Between-subjects
ffects were assessed by one-way analysis of variance (ANOVA).
ifferences between groups were then determined by a Tukey’s hon-
stly significant difference test (Tukey HSD) post hoc analysis. The
esults are expressed as group means± standard error. Statistical
ignificance was accepted for a probability level below 0.05.
. Results
.1. Evaluation of the open arm avoidance effect
As illustrated in Table 1, the repeated measures analysis
f variance (ANOVA) performed revealed significant effect
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Table 1
Two-factor (age group× trial) repeated measures ANOVA
Parameter Age group (d.f. = 3.90) Trial (d.f. = 1.90) Age group× trial (d.f. = 3.90)
% Open arm time F= 6.684; p< 0.001 F= 77.794; p< 0.001 F= 6.465; p= 0.001
% Open arm entries NS F= 212.795; p< 0.001 NS
Closed arm entries F= 14.383; p< 0.001 NS NS
Risk assessment F= 28.095; p< 0.001 F= 30.965; p< 0.001 F= 33.477; p< 0.001
d.f., degrees of freedom; NS, non-significant.
of age for all the parameters evaluated, except for the % of
open arm entries. A significant effect of trial was found in
all the parameters evaluated in the EPM except in the closed
arm entries. Furthermore, this analysis revealed interactions
between age and trial in the % of open arm time and risk
assessment behaviour.
In trial 1, a progressive reduction of the % of time spent in
the open arms of the EPM was observed with increasing age
of maze naive rats. In trial 2, maze-experienced rats revealed
a progressive increase in this parameter with increasing age,
except for the rats of 18 months (Fig. 1).
The intertrial differences analysis, revealed a significant
reduction in the % of time spent in the open arms in trial 2
in rats of 2 months (F(1,23) = 12.645, p= 0.001) and 3 months
(F(1,23) = 4.397, p= 0.047), confirming the OAA effect pre-
viously described. Surprisingly, in older rats [12 months
(F(1,23) = 6.119, p= 0.003) and 18 months (F(1,23) = 5.513,
p= 0.027)], there was an opposite effect, with a significant
increase in the % of time spent in open arms in trial 2.
For the % of open arm entries, the same behavioural pat-
tern was observed, with a significant decrease in trial 2 in
rats of 2 months (F(1,23) = 5.539, p= 0.026) and 3 months
(F(1,23) = 8.777, p= 0.007) but an increase, although not sta-
tistically significant in rats of 12 and 18 months of age (Fig. 1).
The one-way ANOVA performed revealed significant dif-
ferences in the variation in % of time spent in open arms
(T2–T1), between younger rats of 2 months and older rats
of 12 months (p< 0.001) and 18 months (p= 0.001) and be-
tween rats of 3 and 12 months (p= 0.005). The variation in
the % of open arm entries (T2–T1) was significantly different
between younger rats of 2 months and 12 (p= 0.012) and 18
months (p= 0.043) old rats, as well as between rats of 3 and
12 months (p= 0.02).
In the risk assessment behaviour parameter, significant
intertrial differences were found in animals aged 2 months
(p< 0.001) and 18 months (p< 0.001); in both cases, there
was an increase in risk assessment behaviour in the second
trial. No significant intertrial differences were observed in
F
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oig. 1. Changes in the percentage of time spent in the open arms (A) and percen
ercentage of time spent in open arms (C) and percentage of open arm entries (D) be
pen arm time; OAE, open arm entries.tage of open arm entries (B) in the first and second trial. Variation of the
tween trials (T2–T1). *p< 0.05. Data are presented as mean±S.E.M. OAT,
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Fig. 2. Intertrial differences in risk assessment behaviour (A) and total number of closed arm entries (B) in different age groups. *p< 0.05. Data are presented
as mean±S.E.M.
the 3- and 12-month groups. Interestingly, there was a pro-
gressive decline with increasing age in this parameter in trial
1 (Fig. 2).
As a measure of general locomotor activity, the number of
entries in the closed arms failed to reveal any significant inter-
trial differences between age groups. However, a progressive
decrease in this parameter was observed with increasing age,
except for the second trial in the rats of 18 months (Fig. 2).
3.2. One trial tolerance to midazolam
Table 2 illustrates the three-factor (age× drug×maze
experience) analysis of variance (ANOVA) performed to
assess the one trial tolerance to midazolam that revealed a
significant main effect of age for all the parameters evaluated.
A significant effect of maze experience was found for all
the parameters evaluated except for the number of closed
arm entries. The effect of drug was only significant for the
number of closed arm entries and risk assessment behaviour.
Furthermore, this analysis revealed significant interactions
between age and drug for the % of open arm time, age
and maze experience for all the parameters evaluated, drug
and maze experience for all the parameters except risk
assessment behaviour and between the three factors for the
number of closed arm entries.
t
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and lower % of open arm entries (F(1,25) = 98.321, p= 0.04)
whilst maze-experienced rats of 12 months revealed a higher
% of open arm time (F(1,11) = 6.119, p= 0.033).
As illustrated in Fig. 3, in maze naive rats of 3 months,
significant differences were found between the saline treated
group and the midazolam (1 mg/kg) treated group that re-
vealed a higher % of time in the open arms (F(2,26) = 3.952,
p= 0.04) and higher % of open arm entries (F(2,26) = 3.483,
p= 0.044). Maze-experienced rats of 3 months treated with
midazolam (1 mg/kg) revealed a significant lower % of open
arm time (F(2,22) = 3.667, p= 0.035) compared to the saline
treated group and failed to reveal significant differences in
the % of open arm entries, thereby confirming the one trial
tolerance to midazolam previously described.
In maze naive rats of 12 months no significant differences
were found between treatment groups regarding the % of
time spent in the open arms and the % of open arm entries.
Maze-experienced rats of 12 months treated with midazolam
(1 mg/kg) revealed a significantly lower % of open arm time
(F(2,19) = 8.252, p= 0.002) compared with the saline treated
group and a lower, although not significant, % of open arm
entries.
Concerning the number of closed arm entries (Fig. 3),
maze naive rats of 12 months treated with midazolam
(1 mg/kg) revealed a significant lower locomotor activ-
ity compared with the saline (F = 9.361, p= 0.002)
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M = 18.62
A
A = 15.71
D = 5.023
A
dIn accordance with the results of the OAA evalua-
ion, significant differences between maze naive and maze-
xperienced rats were found within the saline treated groups
f different age. Maze-experienced rats at 3 months of age re-
ealed lower % of open arm time (F(1,25) = 4.397, p= 0.047)
able 2
hree-factor (age× drug×maze experience) ANOVA
arameter % Open arm time %
ge (d.f. = 1.90) F= 6.799; p= 0.011 F
rug (d.f. = 1.90) NS NS
aze experience (d.f. = 1.90) F= 8.178; p= 0.005 F
ge× drug F= 6.197; p= 0.003 NS
ge×maze experience F= 39.502; p< 0.001 F
rug×maze experience F= 10.064; p< 0.001 F
ge× drug×maze experience NS NS
.f., degrees of freedom; NS, non-significant.(2,19)
nd midazolam (0.5 mg/kg) treated group (F(2,19) = 9.361,
= 0.01). Maze-experienced rats of 12 months treated with
idazolam (1 mg/kg) showed a lower locomotor activ-
ty compared with midazolam (0.5 mg/kg) treated group
rm entries Closed arm entries Risk assessment
; p= 0.01 F= 41.622; p< 0.001 F= 41.285; p< 0.001
F= 9.890; p< 0.001 F= 3.325; p= 0.041
5; p< 0.001 NS F= 6.971; p= 0.01
NS NS
4; p< 0.001 F= 7.083; p= 0.006 F= 6.854; p= 0.011
; p= 0.009 F= 5.255; p= 0.007 NS
F= 4.225; p= 0.018 NS
J.M. Bessa et al. / Behavioural Brain Research 162 (2005) 135–142 139
Fig. 3. (A) Effects of midazolam on the % of time spent in the open arms. The insets compare % of open arm time in maze-naive and maze-experienced rats
given different doses of midazolam at 3 (A1) and 12 (A2) months of age. (B) Effects of midazolam on the % of entries in the open arms. Insets show the effects
of different doses of midazolam on the % of open arm entries in maze-naive and maze-experienced rats at 3 (B1) and 12 (B2) months of age. (*) Statistical
differences between treatment groups + statistical differences between maze-naive and maze-experienced groups. Data are presented as mean±S.E.M.
(F(2,19) = 7.085, p= 0.0014) which revealed a higher lo-
comotor activity compared with the saline treated group
(F(2,19) = 7.085, p= 0.0013). In the age group of 3 months,
significant differences in this parameter were exclusively
found in maze-experienced rats in which the midazolam
(0.5 mg/kg) treated group revealed higher scores compared
to saline (F(2,22) = 7.167, p= 0.021) and midazolam (1 mg/kg)
(F(2,22) = 7.167, p= 0.004) treated rats.
In the risk assessment behaviour parameter, signifi-
cant differences were confined to the maze-experienced
rats of 3 months, in which the midazolam (0.5 mg/kg)
treated group revealed a higher score compared with the
saline (F(2,22) = 8.834, p= 0.01) and midazolam (1 mg/kg)
(F(2,22) = 8.834, p= 0.028) treated rats (Fig. 4).
4. Discussion
Aging is a multifactorial process that leads to neurobehav-
ioral declines, although at different rates. Changes in emo-
tional behaviour, including increased anxiety behaviour, rep-
resent one of the most important aspects of aging. This is
perfectly illustrated by the analysis of medical prescription
in aged persons, which is characterised by a significant in-
crease in the use of anxiolytic drugs [9]. In accordance with
other studies in rodents [6,25], we observed in the first trial
of the EPM a progressive decrease in the % of time spent
in the open arms and locomotor activity with increasing age.
Interestingly, the % of time spent in the open arm declined
consistently from the younger (2-month-old) to the older (18-
month-old) groups of animals tested; age-associated declines
in open arm entries, another marker of anxiety, were less ob-
vious.
Also in agreement with literature [2,12,16,19,23,34] our
results confirm that retesting young adults (2- and 3-month-
old animals) in the EPM increases open arm avoidance, as
shown by the significant decrease of the % of time and open
arm entries in the second trial. Rather surprisingly, an oppo-
site effect was observed in mid-age rats (12 months) and old
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Fig. 4. Midazolam (0.5–1 mg/kg) effects on risk assessment behaviour (A) and total number of closed arm entries (B), in both maze-naive and maze-experienced
(drug-naive) rats submitted to the EPM. (*) Statistical differences between treatment groups. Data are presented as mean±S.E.M.
rats (18 months), in which retesting produced a significant
increase in the % of time spent in the open arms of the EPM
in trial 2.
The mechanisms underlying both OAA and OTT are far
from completely understood. It has been hypothesized that
fear cues, known to be rapidly acquired during trial 1, might
trigger endocannabinoid activation on plus-maze trial 2 [37].
Of direct relevance to this line of argument is a recent report
that re-exposure to learned fear cues selectively increases en-
docannabinoid levels in the basolateral amygdala [28], an
area of brain crucial for emotional behaviour. Endocannabi-
noid increases become further relevant, when considering
that activation of presynaptic cannabinoid receptors inhibits
neurotransmitter release in several areas of the brain [13,39]
reducing particularly the GABAergic neurotransmission in
limbic regions [1,7,31,38,40,43] a fact that might lead to in-
crease basal anxiety relative to trial 1.
Because endocannabinoids are involved in learning and
memory processes [8], their implication in OAA becomes
further supported by observations showing that drugs (e.g.
scopolamine) interfering with learning acquisition can blunt
the OTT phenomenon [5]. Given that age is characteristically
associated with impairments in learning processes, including
fear conditioning [26], one might speculate that age-induced
deficits in fear acquisition might be essential to the absence of
avoidance to the open arm in re-exposures to the EPM. Fur-
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progressive decrease of risk assessment behaviour with ag-
ing, in both trials. However, significant intertrial variations
in this parameter were confined to the youngest (2-month-
old) or oldest (18-month-old) groups, in which there was an
increased risk assessment in re-exposure to the EPM. This
observation demonstrates that both developing (immature)
and senescent rats display a different exploratory strategy
when re-exposed to an anxiety model, suggesting a curious
age-associated quantitative shift in anxious behaviour in age
extremes.
Administration of midazolam to young maze-naive rats
produced an anxiolytic effect; as expected, the anxiolytic
effects of midazolam were compromised in young maze-
experienced rats. Curiously, the age of the subject affected
the response to these drugs, as in older animals similar doses
of midazolam failed to produce significant anxiolytic effects,
suggesting an increased “resistance” and/or reduced den-
sity of GABA-A receptors in aged-subjects. Furthermore,
1 mg/kg of midazolam produced sedation in older animals, a
finding that is in agreement with previous observations that
the behavioural effect of benzodiazepines in aged rats favours
a sedative profile in detriment of their anxiolytic actions [43].
Despite significant interactions between age, drug and
maze experience, these factors influenced behaviour differ-
ently: while, age was the major determinant of the locomotion
(closed arm entries) and risk assessment behaviour, previ-
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phermore, it has been recently shown that CB1 endocannabi-
oid receptor expression and activity is decreased with age
n humans [29].
Irrespective of the mechanisms underlying the open arm
voidance phenomenon and the age-associated differences
erein described, analysis of data allows us to rule out loco-
otor habituation [12] as a key factor in its genesis. In fact,
lthough aging was associated with decreased activity, com-
arison of closed-arm entries between trials did not reveal
ignificant variation in general locomotion activity in any of
he age groups studied.
Repeated measures analysis of variance confirmed a sig-
ificant effect of age in risk assessment behaviour, with aus maze experience had the greatest influence on anxiety
ehaviour (% of time in open arms and % of open arm en-
ries). Interestingly the latter factor per se failed to influence
he number of closed arm entries (locomotion). Importantly,
hen assessing the one trial tolerance phenomenon to mi-
azolam in different ages it becomes clear that the latter is
reserved independently of the age of the subject. Yet, com-
arisons of % of open arm time and entries between age-
atched maze-naive versus maze-experienced animals re-
ealed significant differences only in younger subjects. The
ack of significant differences of previous maze experience in
lder animals is due to the paradoxical open arm avoidance
reviously observed rather than to an altered profile in drug
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response in the second trial of the maze. In other words, the
apparent effect of age in the tolerance to midazolam should
not be ascribed to an altered response to the drug but instead
to the altered behaviour pattern in the re-exposure to the maze
observed in drug-free animals: while in young animals there
was a significant avoidance to open arms, re-exposure of old
saline treated rats to the EPM was associated with a prefer-
ence to open arms.
The paradoxical effect of aging in open arm avoidance,
as well as the shift towards a predominant sedative response
to benzodiazepines in aged animals, illustrates a qualitative
change in emotional behaviour with increasing age that might
influence the efficacy of anxiolytic drugs in elder subjects.
The present results suggest that alterations in GABA-A re-
ceptor activity during the lifespan [41,44] may underlie re-
sistance to conventional anxiolytic agents. Thus, improved
treatment outcome in anxiety disorders in older subjects will
benefit from the design of pharmacological agents that are
customized to meet the challenges of an altered neurochem-
ical substrate during aging.
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